141 related articles for article (PubMed ID: 38804254)
21. Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy.
Ravasio R; Costanzo A; Antonelli S; Maiorino A; Losi S
Glob Reg Health Technol Assess; 2021; 8():53-57. PubMed ID: 36627878
[TBL] [Abstract][Full Text] [Related]
22. Biologics for Psoriasis.
Wride AM; Chen GF; Spaulding SL; Tkachenko E; Cohen JM
Dermatol Clin; 2024 Jul; 42(3):339-355. PubMed ID: 38796266
[TBL] [Abstract][Full Text] [Related]
23. Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.
Prignano F; Pescitelli L; Trovato E; DI Cesare A; Cuccia A; Mazzatenta C; Pellegrino M; Marsili F; Castelli A; Brandini L; Niccoli MC; Taviti F; Ricceri F; Panduri S; Buggiani G; Ghilardi A; Rubegni P; Romanelli M; Pimpinelli N
Ital J Dermatol Venerol; 2022 Dec; 157(6):469-479. PubMed ID: 35785927
[TBL] [Abstract][Full Text] [Related]
24. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version).
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Sano S; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 Feb; 50(2):e41-e68. PubMed ID: 36582113
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
Fitzgerald T; Zhdanava M; Pilon D; Shah A; Hilts A; Lefebvre P; Feldman SR
Dermatol Ther (Heidelb); 2023 Apr; 13(4):1053-1068. PubMed ID: 36929120
[TBL] [Abstract][Full Text] [Related]
26. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
27. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO).
Travaglini M; Maul JT; Kors C; Zaheri S; Gerwien J; Müller M; Brnabic A; Sabatino S; Schuster C; Tsai TF
Clin Cosmet Investig Dermatol; 2023; 16():2971-2983. PubMed ID: 37881205
[TBL] [Abstract][Full Text] [Related]
29. Anti-drug antibodies of IL-17 inhibitors for psoriasis: a systematic review.
Norden A; Oulee A; Munawar L; Javadi SS; Han G; Wu JJ
J Dermatolog Treat; 2022 Dec; 33(8):3080-3085. PubMed ID: 35972196
[TBL] [Abstract][Full Text] [Related]
30. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis.
Gisondi P; Geat D; Pizzolato M; Girolomoni G
Curr Opin Pharmacol; 2019 Jun; 46():90-99. PubMed ID: 31212119
[TBL] [Abstract][Full Text] [Related]
31. Biologics in the treatment of pustular psoriasis.
Wang WM; Jin HZ
Expert Opin Drug Saf; 2020 Aug; 19(8):969-980. PubMed ID: 32615817
[TBL] [Abstract][Full Text] [Related]
32. Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors.
Huang YH; Chang LC; Chang YC; Chung WH; Yang SF; Su SC
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902001
[TBL] [Abstract][Full Text] [Related]
33. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
[TBL] [Abstract][Full Text] [Related]
34. Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.
Blauvelt A; Gooderham M; Griffiths CEM; Armstrong AW; Zhu B; Burge R; Gallo G; Guo J; Garrelts A; Lebwohl M
Dermatol Ther (Heidelb); 2022 Mar; 12(3):727-740. PubMed ID: 35195887
[TBL] [Abstract][Full Text] [Related]
35. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
36. Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis.
Armstrong A; Xia Q; John AR; Patel V; Seigel L
Dermatol Ther (Heidelb); 2022 Sep; 12(9):2087-2103. PubMed ID: 35947341
[TBL] [Abstract][Full Text] [Related]
37. On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study.
Sermsaksasithorn P; Wongtada C; Chaaim V; Chongpison Y; Asawanonda P
J Dermatolog Treat; 2022 Nov; 33(7):2963-2974. PubMed ID: 35695280
[TBL] [Abstract][Full Text] [Related]
38. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.
Mahil SK; Ezejimofor MC; Exton LS; Manounah L; Burden AD; Coates LC; de Brito M; McGuire A; Murphy R; Owen CM; Parslew R; Woolf RT; Yiu ZZN; Uthman OA; Mohd Mustapa MF; Smith CH
Br J Dermatol; 2020 Oct; 183(4):638-649. PubMed ID: 32562551
[TBL] [Abstract][Full Text] [Related]
39. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Guelimi R; Garcia-Doval I; Hua C; Hughes C; Naldi L; Kinberger M; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011535. PubMed ID: 37436070
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
